[go: up one dir, main page]

WO2024191702A3 - P-selectin inhibition to treat human lymphedema - Google Patents

P-selectin inhibition to treat human lymphedema Download PDF

Info

Publication number
WO2024191702A3
WO2024191702A3 PCT/US2024/018719 US2024018719W WO2024191702A3 WO 2024191702 A3 WO2024191702 A3 WO 2024191702A3 US 2024018719 W US2024018719 W US 2024018719W WO 2024191702 A3 WO2024191702 A3 WO 2024191702A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphedema
treat human
selectin inhibition
human lymphedema
selectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/018719
Other languages
French (fr)
Other versions
WO2024191702A2 (en
Inventor
Mark R. Nicolls
Amy TIAN
Xinguo JIANG
Dongeon KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
Leland Stanford Junior University
Original Assignee
US Department of Veterans Affairs
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, Leland Stanford Junior University filed Critical US Department of Veterans Affairs
Publication of WO2024191702A2 publication Critical patent/WO2024191702A2/en
Publication of WO2024191702A3 publication Critical patent/WO2024191702A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Provided are therapeutic methods for treating a patient with lymphedema, or for prophylactically treating an individual susceptible to lymphedema, by blocking P-selectin activity.
PCT/US2024/018719 2023-03-10 2024-03-06 P-selectin inhibition to treat human lymphedema Pending WO2024191702A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363451488P 2023-03-10 2023-03-10
US63/451,488 2023-03-10

Publications (2)

Publication Number Publication Date
WO2024191702A2 WO2024191702A2 (en) 2024-09-19
WO2024191702A3 true WO2024191702A3 (en) 2024-10-24

Family

ID=92755785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/018719 Pending WO2024191702A2 (en) 2023-03-10 2024-03-06 P-selectin inhibition to treat human lymphedema

Country Status (1)

Country Link
WO (1) WO2024191702A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180193296A1 (en) * 2015-03-13 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
US20190241665A1 (en) * 2018-01-25 2019-08-08 Wisconsin Alumni Research Foundation Methods of inhibiting metastasis in cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180193296A1 (en) * 2015-03-13 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
US20190241665A1 (en) * 2018-01-25 2019-08-08 Wisconsin Alumni Research Foundation Methods of inhibiting metastasis in cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM DONGEON, TIAN WEN, WU TIMOTHY TING-HSUAN, XIANG MENGLAN, VINH RYAN, CHANG JASON, GU SHENBIAO, LEE SEUNGHEE, ZHU YU, GUAN TORRE: "Abnormal lymphatic S1P signaling aggravates lymphatic dysfunction and tissue inflammation", MEDRXIV, 12 June 2023 (2023-06-12), XP093226567, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2023.06.08.23291175v1.full.pdf> DOI: 10.1101/2023.06.08.23291175 *
PFISTER ET AL.: "Sodium selenite and cancer related lymphedema: Biological and pharmacological effects", JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, vol. 37, 26 July 2016 (2016-07-26), pages 111 - 116, XP029663019, DOI: 10.1016/j.jtemb.2016.05.005 *

Also Published As

Publication number Publication date
WO2024191702A2 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
MX2023005455A (en) Methods of treating heart failure by administering omecamtiv mecarbil.
WO2020121310A3 (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3954429A3 (en) Systems for controlling blood pressure
EP4346664A4 (en) Tissue treatment system
MX2021010173A (en) Compounds with ferroptosis inducing activity and methods of their use.
WO2010002936A3 (en) Systems, methods and devices for paired plasticity
MX2022003193A (en) TREATMENT OF ENCEPHALOPATHY ASSOCIATED WITH THE SYNGAP1 GENE.
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
EP3590338A3 (en) Medical treatments based on anamorelin
BR112013007423A2 (en) combination therapy with regard to the treatment of hcv infection
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
WO2021231931A8 (en) Methods of treating sars-cov-2 infections
WO2024191702A3 (en) P-selectin inhibition to treat human lymphedema
WO2022178255A3 (en) Single domain antibodies that neutralize sars-cov-2
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
WO2023240199A3 (en) Fitusiran for the treatment of hemophilia a and b
BR112021020962A2 (en) Pruritus treatment methods
WO2009013480A3 (en) Antibacterial combination therapy
WO2022081610A8 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
WO2023150703A3 (en) Methods of treatment using t-type calcium channel modulators
EP4491231A3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
NO20063320L (en) Use of gaboxadol for the treatment of insomnia
WO2006047625A3 (en) Method to promote wound healing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24771412

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE